May 29, 2020New England Journal of Medicine1,340 citationsOpen Access
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
View Full Paper
Key Points
Key points are not available for this paper at this time.
Abstract
Therapy with trastuzumab deruxtecan led to significant improvements in response and overall survival, as compared with standard therapies, among patients with HER2-positive gastric cancer. Myelosuppression and interstitial lung disease were the notable toxic effects. (Funded by Daiichi Sankyo; DESTINY-Gastric01 ClinicalTrials.gov number, NCT03329690.).
Cite This Study
Shitara et al. (2020) studied this question.